Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.
Also called NCT01150357
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 267 participants
- Sponsor
- Registry
-
NCT01150357 -
2009-017028-22
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Germany, Guatemala, Hungary, Poland, Puerto Rico, Slovakia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01150357. Randomized; double masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
- Condition
- Hypertension
- Intervention (Drug)
- Aliskiren (6.25/12.5/25 mg)
- Intervention (Drug)
- Aliskiren (37.5/75/150 mg)
- Intervention (Drug)
- Aliskiren (150/300/600 mg)
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01150357- Content hash
2384f0ae8e81584740fd9f2554253e522127841772b3b4e19f6525b695a06e86